Press Releases
Sep 26, 2019
Summary ToggleArbitration Decision Affirms Intellia Therapeutics’ Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology
Interim Award concluded all technology in dispute was exclusively licensed to Intellia Parties must negotiate terms and payments to Intellia for Caribou’s use of the chemically modified guide RNAs CAMBRIDGE, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Aug 1, 2019
Summary ToggleIntellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update
NTLA-2001: Intends to submit an investigational new drug application in mid-2020 for lead in vivo program for the treatment of transthyretin amyloidosis On track to nominate first engineered cell therapy development candidate for the treatment of acute myeloid leukemia by end of 2019 Ends quarter
Jul 30, 2019
Summary ToggleIntellia Therapeutics to Present at August Healthcare Investor Conference
CAMBRIDGE, Mass. , July 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the following upcoming healthcare conference in
Jul 25, 2019
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update
CAMBRIDGE, Mass. , July 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present second quarter 2019 results and operational highlights in
Jun 26, 2019
Summary ToggleIntellia Therapeutics’ Statement on Recent U.S. Patent and Trademark Office Actions Relating to Key CRISPR/Cas9 Genome Editing Technology
New patent interference proceeding initated by the United States Patent and Trademark Office (USPTO) will determine if the University of California, University of Vienna and Emmanuelle Charpentier (UC Group) were first to invent the use of CRISPR/Cas9 in eukaryotic cells, which could result in up
May 30, 2019
Summary ToggleIntellia Therapeutics to Participate at June Healthcare Investor Conferences
CAMBRIDGE, Mass. , May 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will participate in the following upcoming healthcare conferences in
May 28, 2019
Summary ToggleIntellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer
CAMBRIDGE, Mass. , May 28, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. , (NASDAQ:NTLA) has named Laura Sepp-Lorenzino , Ph.D., as its new executive vice president and chief scientific officer. Dr. Sepp-Lorenzino brings decades of leadership and research and development experience, and
May 2, 2019
Summary ToggleIntellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update
Remains on track to submit investigational new drug application in 2020 for its first systemically delivered CRISPR/Cas9-based therapy, NTLA-2001, for treatment of transthyretin amyloidosis Expects to nominate first engineered cell therapy development candidate for treatment of acute myeloid
Apr 29, 2019
Summary ToggleIntellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
Intellia scientists advance CRISPR-mediated targeted gene insertion in non-human primates Achieved normal circulating human Factor IX protein levels in non-human primates using targeted gene insertion High rate and specificity of acute myeloid leukemia cell killing progressed using genome-edited,
Apr 25, 2019
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update
CAMBRIDGE, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present first quarter 2019 results and operational highlights in
